Top Markets
#1 Islamic Coin Islamic Coin +152.31%
#2 Bitway Bitway +49.30%
#3 Starpower Starpower +37.29%
#4 aelf aelf +29.81%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +28.60%
#6 SkyAI SkyAI +19.80%
#7 Pons Pons +17.13%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.08%
#9 Decred Decred +14.08%
#10 Bedrock Bedrock +13.96%
Coin of the day
Islamic Coin Islamic Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Medivir AB (publ) Medivir AB (publ)

Medivir AB (publ)

MVIR-B
Rang in Aktien #29654
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Aktienkurs
$0.68377137
Zuletzt synchronisiert: 2023-05-23
Marktkapitalisierung
$20.23M
Veränderung (1 Tag)
-0.60%
Veränderung (1 Jahr)
0.00%
Land
SE
Handel Medivir AB (publ) (MVIR-B)

Kategorie

Healthcare
P/B-Verhältnis für Medivir AB (publ) (MVIR-B)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Medivir AB (publ) beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Medivir AB (publ) von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR